BCLAF1 CRISPR/Cas9 KO Plasmid (m): sc-428381
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- BCLAF1 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the BCLAF1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: BCLAF1 Antibody (M33-P5B11): sc-101388
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
BCLAF1 CRISPR/Cas9 KO Plasmid (m) | sc-428381 | 20 µg | $397.00 |
Overview
Bclaf1 encodes BCLAF1, a nuclear DNA- and RNA-binding factor implicated in transcriptional regulation, pre-mRNA splicing, and chromatin-associated control of gene expression. BCLAF1 has been linked to DNA damage responses and apoptosis-related programs through interactions with BCL2-family signaling and stress-responsive transcriptional networks. In mouse cells, BCLAF1 contributes to maintenance of genome stability and regulation of cell-cycle and survival pathways that shape developmental and immune-relevant gene expression. Dysregulated BCLAF1 activity has been associated with altered proliferative capacity and aberrant RNA processing phenotypes relevant to cancer biology and neuroimmune signaling contexts.
BCLAF1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Bclaf1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Bclaf1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Bclaf1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish BCLAF1 protein expression.
This CRISPR knockout system enables efficient generation of Bclaf1-deficient cell models for investigation of BCLAF1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Bclaf1 exon(s) critical for BCLAF1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Bclaf1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by BCLAF1 CRISPR/Cas9 KO Plasmid (m) and BCLAF1 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Bclaf1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by BCLAF1 HDR Plasmid (m) and BCLAF1 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Bclaf1 homology arms to support homology-directed repair at defined Bclaf1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.